{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:09:35Z","timestamp":1790636975607,"version":"4.1.0"},"reference-count":59,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Armolipid Plus\u00ae is a multi-constituent nutraceutical that claims to improve lipid profiles. The aim of this PRISMA compliant systematic review and meta-analysis was to globally evaluate the efficacy and safety of Armolipid Plus\u00ae on the basis of the available randomized, blinded, controlled clinical trials (RCTs). A systematic literature search in several databases was conducted in order to identify RCTs assessing the efficacy and safety of dietary supplementation with Armolipid Plus\u00ae. Two review authors independently identified 12 eligible studies (1050 included subjects overall) and extracted data on study characteristics, methods, and outcomes. Meta-analysis of the data suggested that dietary supplementation with Armolipid Plus\u00ae exerted a significant effect on body mass index (mean difference (MD) = \u22120.25 kg\/m2, p = 0.008) and serum levels of total cholesterol (MD = \u221225.07 mg\/dL, p &lt; 0.001), triglycerides (MD = \u221211.47 mg\/dL, p &lt; 0.001), high-density lipoprotein cholesterol (MD = 1.84 mg\/dL, p &lt; 0.001), low-density lipoprotein cholesterol (MD = \u221226.67 mg\/dL, p &lt; 0.001), high sensitivity C reactive protein (hs-CRP, MD = \u22120.61 mg\/L, p = 0.022), and fasting glucose (MD = \u22123.52 mg\/dL, p &lt; 0.001). Armolipid Plus\u00ae was well tolerated. This meta-analysis demonstrates that dietary supplementation with Armolipid Plus\u00ae is associated with clinically meaningful improvements in serum lipids, glucose, and hs-CRP. These changes are consistent with improved cardiometabolic health.<\/jats:p>","DOI":"10.3390\/nu13020638","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T08:09:09Z","timestamp":1613462949000},"page":"638","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and Safety of Armolipid Plus\u00ae: An Updated PRISMA Compliant Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4367-3884","authenticated-orcid":false,"given":"Arrigo F. G.","family":"Cicero","sequence":"first","affiliation":[{"name":"Hypertension and Atherosclerosis Research Group, Medical and Surgical Sciences Department, Sant\u2019Orsola-Malpighi University Hospital, 40138 Bologna, Italy"},{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Italian Nutraceutical Society (SINut), 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2577-0242","authenticated-orcid":false,"given":"Cormac","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Trinity College Dublin and St James Hospital, Dublin 8, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Kne\u017eevi\u0107","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilisa","family":"Bove","sequence":"additional","affiliation":[{"name":"Hypertension and Atherosclerosis Research Group, Medical and Surgical Sciences Department, Sant\u2019Orsola-Malpighi University Hospital, 40138 Bologna, Italy"},{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7062-6653","authenticated-orcid":false,"given":"Coralie M. G.","family":"Georges","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain, 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u0117","family":"\u0160atrauskien\u0117","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania"},{"name":"Vilnius University Hospital Santari\u0161kiu Klinikos, LT-08661 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[{"name":"CGH Medical Center, Sterling, IL 61081, USA"},{"name":"Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7853-0042","authenticated-orcid":false,"given":"Federica","family":"Fogacci","sequence":"additional","affiliation":[{"name":"Hypertension and Atherosclerosis Research Group, Medical and Surgical Sciences Department, Sant\u2019Orsola-Malpighi University Hospital, 40138 Bologna, Italy"},{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Italian Nutraceutical Society (SINut), 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2020, December 26). Cardiovascular Diseases. Available online: http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/CIRCULATIONAHA.115.011646","article-title":"Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies","volume":"133","author":"Colantonio","year":"2016","journal-title":"Circulation"},{"key":"ref_4","first-page":"e38","article-title":"Heart Disease and Stroke Statistics\u20142016 Update: A Report from the American Heart Association. American Heart Association Statistics Committee, Stroke Statistics Subcommittee","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"ref_5","unstructured":"NCD Risk Factor Collaboration (NCD-RisC), Taddei, C., Jackson, R., Zhou, B., Bixby, H., Danaei, G., Di Cesare, M., Kuulasmaa, K., Hajifathalian, K., and Bentham, J. (2019). National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: A pooled analysis of 458 population-based studies in Asian and Western countries. Int. J. Epidemiol., 49, 173\u2013192."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1161\/CIR.0000000000000626","article-title":"Systematic Review for the 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Wilson","year":"2019","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zeitouni, M., Sabouret, P., Kerneis, M., Silvain, J., Collet, J.-P., Bruckert, E., and Montalescot, G. (2020). 2019 ESC\/EAS Guidelines for management of dyslipidaemia: Strengths and limitations. Eur. Hear. J. Cardiovasc. Pharmacother., 77.","DOI":"10.1093\/ehjcvp\/pvaa077"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2016.05.037","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice","volume":"252","author":"Piepoli","year":"2016","journal-title":"Atherosclerosis"},{"key":"ref_9","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.phrs.2018.05.015","article-title":"Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper","volume":"134","author":"Poli","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/nutrit\/nux047","article-title":"Lipid-lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel","volume":"75","author":"Cicero","year":"2017","journal-title":"Nutr. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.2174\/1381612823666170317145851","article-title":"Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia","volume":"23","author":"Patti","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1039\/C7FO00178A","article-title":"Food and plant bioactives for reducing cardiometabolic disease risk: An evidence based approach","volume":"8","author":"Cicero","year":"2017","journal-title":"Food Funct."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.003","article-title":"A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence","volume":"24","author":"Barrios","year":"2017","journal-title":"Atheroscler. Suppl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"For the PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"ref_16","unstructured":"Higgins, J., and Green, S. (2010). Cochrane Handbook for Systematic Reviews of Interventions, John Wiley and Sons Ltd.. Report Version 5.0.2.2009."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40265-019-01114-z","article-title":"Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","volume":"79","author":"Fogacci","year":"2019","journal-title":"Drugs"},{"key":"ref_18","unstructured":"Borenstein, M., Hedges, L., Higgins, J., and Rothstein, H. (2005). Comprehensive Meta-Analysis Version 3, Biostat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J. Clin. Epidemiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res. Methodol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/1469-0691.12494","article-title":"The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses","volume":"20","author":"Melsen","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0021-9681(56)90049-2","article-title":"Statistical approaches to the study of cancer with particular reference to case registers","volume":"4","author":"Haenszel","year":"1956","journal-title":"J. Chronic Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/dom.13324","article-title":"Resveratrol effect on patients with non-alcoholic fatty liver disease: A matter of dose and treatment length","volume":"20","author":"Fogacci","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Fogacci, F., Rizzo, M., Krogager, C., Kennedy, C., Georges, C.M., Kne\u017eevi\u0107, T., Liberopoulos, E., Vall\u00e9e, A., P\u00e9rez-Mart\u00ednez, P., and Wenstedt, E.F. (2020). Safety Evaluation of \u03b1-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies. Antioxidants, 9.","DOI":"10.3390\/antiox9101011"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and Fill: A Simple Funnel-Plot-Based Method of Testing and Adjusting for Publication Bias in Meta-Analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4330\/wjc.v4.i3.77","article-title":"A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome","volume":"4","author":"Affuso","year":"2012","journal-title":"World J. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.numecd.2009.05.017","article-title":"Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study","volume":"20","author":"Affuso","year":"2010","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13749-012-0018-y","article-title":"Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients","volume":"11","author":"Cicero","year":"2012","journal-title":"Nutrafoods"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2147\/DDDT.S128623","article-title":"Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q10 on lipid levels: A randomized, double-blind, placebo controlled study","volume":"11","author":"Scandiani","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12944-019-1002-y","article-title":"Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: A multicenter, double blind, randomized, placebo controlled trial","volume":"18","author":"Galletti","year":"2019","journal-title":"Lipids Heal. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2217\/clp.15.37","article-title":"Effects of Armolipid Plus on small dense LDL particles in a sample of patients affected by familial combined hyperlipidemia","volume":"10","author":"Gentile","year":"2015","journal-title":"Clin. Lipidol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2014.07.003","article-title":"Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols, and Berberine) in Patients with Low-Moderate Risk Hypercholesterolemia: A Double-Blind, Placebo-Controlled Study","volume":"77","author":"Gonnelli","year":"2015","journal-title":"Curr. Ther. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.amjcard.2017.06.015","article-title":"Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients with a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial)","volume":"120","author":"Marazzi","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s12325-011-0082-5","article-title":"Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients","volume":"28","author":"Marazzi","year":"2011","journal-title":"Adv. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.clnu.2019.06.026","article-title":"A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial","volume":"39","author":"Mercurio","year":"2020","journal-title":"Clin. Nutr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jacl.2013.11.003","article-title":"Nutraceutical approach to moderate cardiometabolic risk: Results of a randomized, double-blind and crossover study with Armolipid Plus","volume":"8","author":"Ruscica","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Sola, R., Valls, R.-M., Puzo, J., Calabuig, J.-R., Brea, A., Pedret, A., Mori\u00f1a, D., Villar, J., Mill\u00e1n, J., and Anguera, A. (2014). Effects of Poly-Bioactive Compounds on Lipid Profile and Body Weight in a Moderately Hypercholesterolemic Population with Low Cardiovascular Disease Risk: A Multicenter Randomized Trial. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101978"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.phrs.2016.04.021","article-title":"The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta-analysis of randomized controlled trials","volume":"110","author":"Pirro","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.arteri.2016.03.002","article-title":"Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: A meta-analysis of randomised controlled trials","volume":"28","author":"Cicero","year":"2016","journal-title":"Cl\u00edn. Investig. Arterioscler."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.phanu.2013.02.003","article-title":"Nutraceutical combination (red yeast rice, berberine and policosanols) improves aortic stiffness in low-moderate risk hypercholesterolemic patients","volume":"1","author":"Pirro","year":"2013","journal-title":"PharmaNutrition"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1097\/HJH.0b013e3283395208","article-title":"Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia","volume":"28","author":"Izzo","year":"2010","journal-title":"J. Hypertens."},{"key":"ref_42","first-page":"133","article-title":"Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet","volume":"4","author":"Trimarco","year":"2011","journal-title":"Med. J. Nutrition. Metab."},{"key":"ref_43","first-page":"26","article-title":"Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents: A single-blind clinical investigation","volume":"57","author":"Cicero","year":"2007","journal-title":"Arzneimittelforschung"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1476-511X-11-123","article-title":"Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment","volume":"11","author":"Pisciotta","year":"2012","journal-title":"Lipids Heal. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jacc.2018.04.040","article-title":"The Role of Nutraceuticals in Statin Intolerant Patients","volume":"72","author":"Banach","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2019.02.028","article-title":"Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials","volume":"143","author":"Fogacci","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.amjcard.2018.09.041","article-title":"Usefulness of Low-Dose Statin Plus Ezetimibe and\/or Nutraceuticals in Patients with Coronary Artery Disease Intolerant to High-Dose Statin Treatment","volume":"123","author":"Marazzi","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2015.04.004","article-title":"Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain\u2014A systematic review and meta-analysis","volume":"240","author":"Gerards","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1161\/01.CIR.0000139985.81163.CE","article-title":"Xuezhikang, an Extract of Cholestin, Protects Endothelial Function Through Antiinflammatory and Lipid-Lowering Mechanisms in Patients with Coronary Heart Disease","volume":"110","author":"Zhao","year":"2004","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"192","DOI":"10.14797\/mdcj-15-3-192","article-title":"Red Yeast Rice for Hypercholesterolemia","volume":"15","author":"Cicero","year":"2019","journal-title":"Methodist Debakey Cardiovasc. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.amjcard.2010.01.337","article-title":"Red Yeast Rice and Statin-Intolerant Patients","volume":"105","author":"Cicero","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacc.2020.11.056","article-title":"Red Yeast Rice for Hypercholesterolemia","volume":"77","author":"Cicero","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1301\/nr.2003.nov.376-383","article-title":"Role of policosanols in the prevention and treatment of cardiovascular disease","volume":"61","author":"Varady","year":"2003","journal-title":"Nutr. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.numecd.2009.10.015","article-title":"The treatment of hypercholesterolemic children: Efficacy and safety of a combination of red yeast rice extract and policosanols","volume":"21","author":"Guardamagna","year":"2011","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1507\/endocrj.EJ18-0109","article-title":"Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: A systematic literature review and a meta-analysis","volume":"66","author":"Liang","year":"2019","journal-title":"Endocr. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2018.11.026","article-title":"NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial","volume":"280","author":"Pirro","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/13\/2\/638\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:24:47Z","timestamp":1760160287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/13\/2\/638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["nu13020638"],"URL":"https:\/\/doi.org\/10.3390\/nu13020638","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]}}}